LENZ Therapeutics, Inc. LENZ

US Pharmaceuticals

$4.10 ▼ -4.43% ($-0.19)

🔥 High Short Interest

Open $4.18

Prev Close $4.29

Day Range $4.01 – $4.24

52W Range $2.80 – $32.13

Market Cap $134.79M

Beta 2.15

EPS (TTM) $-4.48

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2021-06-25
Shares Out.	31,420,000
Website	lenz-tx.com/ ↗
Phone	13026587581
Employees	152
Revenue	$3.4M
Gross Profit	$2.9M
Net Income	-$31.0M
Free Cash Flow	-$127.7M
Total Assets	$209.7M
Total Liabilities	$17.8M
Equity	$192.0M

About LENZ Therapeutics, Inc.

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

LENZ Therapeutics, Inc. is a publicly traded company under the ticker symbol LENZ on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.